Member Info for Cashintime

I view this non dilutive funding award as a stamp of approval for Poolbeg by the industry brains. They will get the approval from the market shortly. Well done the Poolbeg team. Another box ticked as they said they would.

Great RNS released. Non dilutive funding. We are off to the races. Busy at work and barely read. £2.3m funding.

I won't be brave enough to hang in here for 70p but it is entirely possible. If this lines up the way I expect I will get myself into a free carry position. For me this will be at a shareprice of around 13p which may be just around the corner. After all this is the wild west of AIM and anything is possible.
I would like if we got into the more regulated platform of the Nasdaq and then I would ride this one all the way.
I am greatly impressed by the management here and anyone that has followed this company will appreciate the refreshing honest way it is being run. It is in the monetisation cycle now of the company's commercial plan and we may just reap big rewards for our investment here. GLALTHs

This is a justified market price correction we are seeing here. It will not be unbelievable to think that we could have a market cap of £350m which would be the 70p Shareprice.
POLB 001 has been described by the company as a potential blockbuster and we are now on the cusp of knowing if we have hit it out of the park. Our AI unique results are saleable in their own right and may be more valuable than we expect. The data sprouts from a data set that Poolbeg have sourced from Open Orphan. This was an 8 month study and it has turned out to be a winner. We await more details promised in a few weeks. There will be a multi bag correction here I believe by year's end and richly deserved.

Now we are motoring

Our 3rd trial in the LPS study is a 7 day trial. Jeremy tod us it had begun when he made his last presentation on the 8th Nov. It could well have finished by now. Just the results to get the Is dotted and the Ts crossed and make the report any week now.

Looking that we could get back to IPO price sooner that Zak Mir expected.

What's the Sanderson plan for this coming week. Absolutely nothing. Just keep drawing the bag of sand daily.

At IPO we had a market cap of £50m which was made up of £25m and POLB 001 and access to Hvivo data for a couple of years was valued @ £25m. This opened at a shareprice of 10p which rose to 13p and was since dropped t as low as 4.2p as the Bio section fell out of favour.
We should now justifiably making a market correction as we wait for our flagship asset LPS study results which have to possibility to give us a multi bag here as we look to partner with big pharma for phase 3 trials upon good results. This product may become a blockbuster as it may have far reaching uses for more conditions than the RSV it was originally intended for. These other uses may be identified by the unique data AI study that reaped positive results just this week. We await further information on these results in the next few weeks. We also have 002 and 003 in the stable both promising products in their own right. All IP and patents progressed nicely to protect our products and concept.
We are now at the stage of partnership and monetisation as we follow the capital light model and successful completion of targets and timelines given by the company. We have an industry leading management team driving this model forward as we look for a market slice of a multi billion pound market.
Alot hinges at positive LPS study results which we will have preliminary results for in the coming weeks.
We have plans to soon go to the Nasdaq market. We could attract large II interest or some Pharma may attempt to take a large stake here at any time.
In other words we can easily multi bag from here as news flow on many fronts is incoming and we come out from under the radar.

Another good day for Poolbeg. We will be passing Hvivo out in Shareprice shortly if it keeps rising to true value. They are getting a raw deal over there when they are closing multi million pound contract after contract.

Looking to break 8p today by the look of things. On the final hurdle for ground breaking news

Fully agree Silver, 70p would be a market cap of £350 million and that is entirely possible with the success of Polb 001 and big pharma partnership of the right calibre . 10p first hurdle. We should have never dropped below IPO price in the first place.
We are in the final 3rd trial phase with the strongest dose given to a selection of 9 candidates. The low and medium dose trials are complete and there must be already some indication of success or failure by those carrying out the test. News probably in the next few weeks. I wonder if we will be getting an RNS in the morning after Jeremy's meeting today with head of AI . He may just have further details on drug targets in this pioneering method of research by the super computers utilising various algorithms that otherwise would take years of work. We could get serious upturn here from big Pharma as we are the first with this type of "pristine data"
using data from firstly healthy people ,who got sick and then got better again.
It's up to the MMs if they want to let this one go on a run. It will be nice to see a bit of liquidity back in this share after all that in species share mess I feel held us back. I can see a good Friday performance here tomorrow. Could break 8.5p and above. Let's see.

I do. That's why I take an active interest in this company. I originally bought in a little over 10p and then averaged down when @ 4.2p to bring my average down to a bit over 6p so slightly back in profit at the moment. I would have expected to be @15p by now but the Bio stocks seem out of favour . That is a cycle that I expect to change this winter. We are in the last quarter now which will be the making of this company and I am confident that the deal making will come fast and furious. My chips are on the table and the dice is being rolled. Do you hold a large position yourself.

He cannot give regulated news to the market but in most cases when the flagship is not working out as hopes it is sometimes easy to spot the signs by body language. In such cases one might notice the secondary products being pushed to the front to minimize the risk to the company. This will be done long before any RNS alters course. I myself would like to see 15p . It could of course explode past this on certain interest
I hold a large stake here and am confident of the model . The next 6 weeks will tell alot.

https://youtu.be/bGQMow2rspk

Jeremy with Proactive today

https://www.google.com/url?sa=t&source=web&rct=j&url=https://finance.yahoo.com/amphtml/news/influenza-pipeline-looks-promising-100-153000888.html&ved=2ahUKEwjmle3hx_r5AhVPVsAKHaZUCfkQyM8BKAB6BAgGEAI&usg=AOvVaw0aiR3q1UfB-avar2oyplIR

Shows that our heavy hitters in the industry are aware of our model and products.

Well over halfway stage of the trials will have given certain indication to the Poolbeg team. They remain positive in any correspondence concerning the trial and I believe that reading between the lines tonight on the body language and future direction on the product it will be safe to presume that the direction to monetisation will remain unchanged. We are onto a winner here in my opinion and 001 could have more far reaching applications going forward that the AI model is helping to identify.

This last quarter will certainly be promising for Poolbeg. The preliminary results from the lab must be looking positive for Polb 001. Question time tonight should reveal more. We are undervalued but won't be under the radar for long. Shareprice could take off at any time from now.

The market seems to be awaiting news flow on POLB 001. We will know tomorrow has Jeremy got anything positive to give us on the feedback from the lab. Monetisation is key here I believe.

What is Sanderson playing at. Is he semi retired or what. He is doing absolutely nothing all this year. On your bike.